Circulating Tumor Cells Help Treatment
Posted on: Wednesday, 6 June 2007, 09:00 CDT
Counting circulating tumor cells before and after the start of treatment for patients with metastatic colorectal cancer could help treatment, says a U.S. study.
Study leader Neal J. Meropol, director of the gastrointestinal cancer program at Philadelphia's Fox Chase Cancer Center, and colleagues examined the association between the circulating tumor cell number and progression-free and overall survival for 430 adult patients with metastatic colorectal cancer.
The number of circulating tumor cells was measured at baseline, one month and several other points after the start of treatment. Circulating tumor cells were isolated and counted.
Having three or more circulating tumor cells per 7.5 mL of blood was defined as unfavorable in an initial analysis, while patients with fewer than three circulating tumor cells were considered favorable.
Patients with unfavorable circulating tumor cells had a shorter median survival time, Meropol said in a statement. This was even seen in those patients whose CT scan -- the gold standard for tumor evaluation -- indicated no disease progression.
The findings were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
Source: United Press International
Related Articles
- Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
- New tool targets breast cancer treatment
- Study Showed ALIMTA(R) (Pemetrexed for Injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
- ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (Pemetrexed for Injection)
- Poniard Pharmaceuticals Announces Treatment of First Patient With Picoplatin in Pivotal Phase 3 Small Cell Lung Cancer Trial
- Arresting Stem Cells May Trump Tumor Shrinkage in Rating Cancer Treatments, Researcher Says
- Tumor Profiles May Help Cancer Treatment
- Vion Initiates Phase II Trial of Cloretazine(R) in Small Cell Lung Cancer
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
- Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients With Non-Small Cell Lung Cancer
User Comments (0)


RSS Feeds